Vyndaqel patent expiry uk?

When did the UK patent on Vyndaqel expire?
The main patent covering Vyndaqel in the United Kingdom—issued to Biogen in the mid‑2000s—has already lapsed. The product is no longer under patent protection in the UK.

Are any other patents or exclusivities still protecting Vyndaqel in the UK?
After the expiry of the original formulation patent, there are no additional UK patents that cover Vyndaqel itself. The drug is not granted orphan‑drug exclusivity or any other special market exclusivity in the UK, so the generic pathway is open.

Can a generic or biosimilar launch in the UK now?
Because the core patent has expired and no exclusivity period remains, a generic manufacturer can apply for a licence and submit an application to the Medicines and Healthcare products Regulatory Agency (MHRA) for a generic version. The process is the same as for any off‑patent drug: an application for a licence to supply, followed by a separate generic approval application (GRA).

What effect does the patent expiry have on price and market access?
When a drug loses patent protection, the entry of generic competitors typically drives down price. In the UK, the National Health Service (NHS) often negotiates lower prices for off‑patent medicines, and private purchasers also benefit from reduced costs. The loss of exclusive rights can also increase the overall supply of Vyndaqel, improving patient access.

How does UK exclusivity differ from EU or US timelines?
Unlike the United States, where a drug can benefit from a 6‑month exclusivity period for a new molecular entity, the UK does not grant any additional exclusivity once the main patent expires. Therefore, the UK timeline is effectively the same as the expiry date of the patent itself, without further protection.

What happens if the manufacturer files a new patent application?
If Biogen were to file a new patent covering a different formulation or delivery method, the new patent would have its own independent expiry date. However, no such application has been publicly disclosed for Vyndaqel in the UK as of the latest available information.